ICUIHealthcare · Medical Instruments & SuppliesThe 8 Wall Street analysts covering ICU Medical, Inc. hold a median 12-month price target of $193 — +19.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 3 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores ICU Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (97): Analysts have, on balance, been raising their forecasts.
Growth (59): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (26): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ICUI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +19.3% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | BTIG | Maintains | Buy | $170 → $200 |
| 7 Aug 2026 | Needham | Maintains | Buy | $165 → $187 |
| 7 Aug 2026 | Piper Sandler | Maintains | Overweight | $163 → $195 |
| 21 July 2026 | Keybanc | Maintains | Overweight | $164 → $182 |
| 21 July 2026 | Keybanc | Maintains | Overweight | — |
| 15 June 2026 | BTIG | Initiates | Buy | — |
| 15 June 2026 | BTIG | Initiates | Buy | $170 |
| 27 May 2026 | Needham | Upgrade | Buy | — |
| 27 Apr 2026 | Keybanc | Maintains | Overweight | — |
| 17 Apr 2026 | Piper Sandler | Maintains | Overweight | — |
| 20 Feb 2026 | Keybanc | Maintains | Overweight | — |
| 20 Feb 2026 | Piper Sandler | Maintains | Overweight | — |
| 7 Nov 2025 | Keybanc | Maintains | Overweight | — |
| 7 Nov 2025 | Piper Sandler | Maintains | Overweight | — |
| 21 Oct 2025 | Keybanc | Maintains | Overweight | — |
| 10 Sept 2025 | Piper Sandler | Maintains | Overweight | — |
| 15 Aug 2025 | Piper Sandler | Initiates | Overweight | — |
| 8 Aug 2025 | Raymond James | Maintains | Strong Buy | — |
| 9 May 2025 | Raymond James | Maintains | Strong Buy | — |
| 21 Apr 2025 | Keybanc | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ICUI appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 5 Oct 2026, ICU Medical, Inc. returned +32.2% against +17.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 5% of US stocks
Cheaper than 54% of US stocks
Cheaper than 47% of US stocks
Cheaper than 22% of US stocks
Higher than 28% of US stocks
Higher than 12% of US stocks
Higher than 53% of US stocks
Higher than 60% of US stocks
Higher than 51% of US stocks
Higher than 46% of US stocks
Higher than 58% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
ICU Medical, Inc. has a market value of $4.0B and an enterprise value of $5.0B.
Revenue in the twelve months to 30 June 2026: $2.2B. The latest quarter grew 0.5% year on year.
Net income over the same four quarters: $30.1M, a 1.4% net margin.
Diluted earnings per share, trailing twelve months: $1.18.
Free cash flow in the twelve months to 30 June 2026: $144.8M.
Trailing P/E: 135.6×; forward P/E: 16.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
ICU Medical, Inc. employs 13,000 people — $166K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own ICU Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
ICU Medical, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation made available on Seeking Alpha.
Why it matters — The presentation gives investors and analysts insight into ICU Medical's current positioning and messaging at a major industry conference.
ICU Medical announced it will participate in the Wells Fargo 21st Annual Healthcare Conference, held September 9-10, 2026 at the Encore Boston Harbor in Boston, MA. Company management will attend and take part in one-on-one meetings during the event.
Why it matters — The conference participation gives investors and analysts an opportunity to engage directly with ICU Medical management, which could provide greater insight into the company.
ICU Medical (NASDAQ:ICUI) reported upbeat earnings for the second quarter on Thursday. Following the results, analysts boosted their forecasts for the company.
Why it matters — The upbeat second-quarter results and ensuing analyst forecast increases signal improving sentiment around ICU Medical's recent performance.
ICU Medical, Inc. held its Q2 2026 earnings call, and the full transcript of the call has been published on Seeking Alpha. The item provides a record of the company's second-quarter 2026 conference call.
Why it matters — An ICUI watcher would care because the earnings call transcript contains management's commentary on the company's quarterly results and outlook.
ICU Medical reported second-quarter revenue of $548 million, up 6% organically and 1% on a reported basis. Growth in its consumables and infusion systems businesses helped offset continued pressure in Vital Care and the effects of the IV Solutions joint venture deconsolidation.
Why it matters — The earnings call highlights organic growth in core businesses while noting ongoing headwinds in Vital Care and the deconsolidation of the IV Solutions joint venture, giving ICUI watchers a factual picture of current performance drivers.
The 8 Wall Street analysts covering ICU Medical, Inc. have a median 12-month price target of $193, with estimates ranging from $178 to $210. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering ICU Medical, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ICU Medical, Inc. 97 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Oct 2026, ICU Medical, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (97 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +19.3% from the last close, and Ticker Nerd's factor model ranks ICU Medical, Inc. 97 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering ICU Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ICUI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $178 to $210 over the next 12 months.
ICU Medical, Inc. returned +32.2% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
ICU Medical, Inc. is a medical technology company focused on infusion therapy, vascular access, and vital care products.
The most recent item we track (Seeking Alpha, 15 Sept 2026): "ICU Medical, Inc. (ICUI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript". ICU Medical, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation made available on Seeking Alpha.
ICU Medical, Inc. is a medical technology company focused on infusion therapy, vascular access, and vital care products. ICU Medical develops, manufactures, and sells a broad portfolio that includes IV pumps, needlefree connectors, IV administration sets, sterile IV solutions, closed-system transfer devices for hazardous drugs, and safety software used in hospital and alternate care settings. The company also offers hemodynamic monitoring, respiratory, anesthesia, temperature management, and other critical care products that support clinical workflows and patient safety. Its product families are designed to help healthcare providers deliver medications and fluids, reduce contamination risks, and improve efficiency across the IV continuum of care. ICU Medical serves acute care hospitals, ambulatory clinics, and home or alternate-site care environments, making it an important supplier in medical devices and hospital infrastructure.
CEO Mr. Vivek Jain · 13,000 employees · United States · https://www.icumed.com
